EyePoint vs Outlook Therapeutics
EYPT and OTLK side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EYPT and OTLK compare
Outlook Therapeutics is the larger company, worth 3.8 times as much as EyePoint ($101M against $26.4M).
EyePoint scores higher on the StockData Score (6 against 4 for Outlook Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EYPT | OTLK |
|---|---|---|
| Size and price | ||
| Market cap | $26.4M | $101M |
| Share price | $0.306 | $0.413 |
| Change, 1 year | −97.4% | −67.7% |
| Change, 5 years | −98.2% | −98.7% |
| Beta (5Y) | 1.71 | 0.97 |
| Employees | 214 | 17 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× | – |
| P/B | 0.2× | – |
| FCF yield | −1134% | – |
| Growth | ||
| Revenue growth (TTM) | −93.9% | – |
| Revenue growth, 5Y average | −1.8% | – |
| Profitability | ||
| Operating margin | −13642% | – |
| Net margin | −13281% | – |
| FCF margin | −11599% | – |
| Return on equity | −222% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 3.30 (better) | 0.81 |
| Altman Z-score | −17.69 (better) | −40.56 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −54.4% |
| Shareholder yield | 0.00% (better) | −54.4% |
| Ownership | ||
| Held by institutions | 108% | 8.4% |
| Held by insiders | 0.96% | 28.5% |
| Insider net buying, 12 months | −$1.9M | $7.9M (better) |
| Short interest, % of float | 12.9% | 20.4% |
Go deeper
- EYPT stock overview
- EYPT income statement
- EYPT valuation and score
- OTLK stock overview
- OTLK income statement
- OTLK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.